Intelligene Inc. (TPEX:7832)

Market Cap	6.76B
Revenue (ttm)	2.39M -49.0%
Net Income	-148.61M
EPS	-0.26
Shares Out	580.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	156,968
Open	11.40
Previous Close	11.50
Day's Range	11.35 - 11.50
52-Week Range	9.37 - 17.65
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 24, 2026

About Intelligene

Intelligene Inc. engages in the research and development of RNA gene therapy drugs in Taiwan and Australia. The company offers IG-001, a siRNA-based drug which is under preclinical trials for the treatment of coronavirus disease; and IG-002, a siRNA-based drug which is under drug screening for the treatment of influenza. It also provides lipid nanoparticle and exosome drug encapsulation technologies to customize drug carriers and develop nucleic acid therapeutics. The company was founded in 2023 and is based in Taipei, Taiwan.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2023
• Employees: 20
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7832

Financial Performance

In 2025, Intelligene's revenue was 2.39 million, a decrease of -48.99% compared to the previous year's 4.68 million. Losses were -148.61 million, 4.55% more than in 2024.